253 related articles for article (PubMed ID: 29467456)
1. Genome-wide CRISPR screen reveals SGOL1 as a druggable target of sorafenib-treated hepatocellular carcinoma.
Sun W; He B; Yang B; Hu W; Cheng S; Xiao H; Yang Z; Wen X; Zhou L; Xie H; Shen X; Wu J; Zheng S
Lab Invest; 2018 Jun; 98(6):734-744. PubMed ID: 29467456
[TBL] [Abstract][Full Text] [Related]
2. Genome-scale CRISPR activation screening identifies a role of LRP8 in Sorafenib resistance in Hepatocellular carcinoma.
Cai J; Chen J; Wu T; Cheng Z; Tian Y; Pu C; Shi W; Suo X; Wu X; Zhang K
Biochem Biophys Res Commun; 2020 Jun; 526(4):1170-1176. PubMed ID: 32312520
[TBL] [Abstract][Full Text] [Related]
3. Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC.
Chan YT; Wu J; Lu Y; Li Q; Feng Z; Xu L; Yuan H; Xing T; Zhang C; Tan HY; Feng Y; Wang N
Mol Cancer; 2024 Apr; 23(1):74. PubMed ID: 38582885
[TBL] [Abstract][Full Text] [Related]
4. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
Song CQ; Li Y; Mou H; Moore J; Park A; Pomyen Y; Hough S; Kennedy Z; Fischer A; Yin H; Anderson DG; Conte D; Zender L; Wang XW; Thorgeirsson S; Weng Z; Xue W
Gastroenterology; 2017 Apr; 152(5):1161-1173.e1. PubMed ID: 27956228
[TBL] [Abstract][Full Text] [Related]
5. CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.
Wang C; Wang H; Lieftink C; du Chatinier A; Gao D; Jin G; Jin H; Beijersbergen RL; Qin W; Bernards R
Gut; 2020 Apr; 69(4):727-736. PubMed ID: 31519701
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide CRISPR knockout screens identify ADAMTSL3 and PTEN genes as suppressors of HCC proliferation and metastasis, respectively.
Zhou X; Li R; Jing R; Zuo B; Zheng Q
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1509-1521. PubMed ID: 32266537
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 screens unravel miR-3689a-3p regulating sorafenib resistance in hepatocellular carcinoma via suppressing CCS/SOD1-dependent mitochondrial oxidative stress.
Lu Y; Chan YT; Wu J; Feng Z; Yuan H; Li Q; Xing T; Xu L; Zhang C; Tan HY; Lee TK; Feng Y; Wang N
Drug Resist Updat; 2023 Nov; 71():101015. PubMed ID: 37924725
[TBL] [Abstract][Full Text] [Related]
8. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC.
Wei L; Lee D; Law CT; Zhang MS; Shen J; Chin DW; Zhang A; Tsang FH; Wong CL; Ng IO; Wong CC; Wong CM
Nat Commun; 2019 Oct; 10(1):4681. PubMed ID: 31615983
[TBL] [Abstract][Full Text] [Related]
10. Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma.
Su WL; Chuang SC; Wang YC; Chen LA; Huang JW; Chang WT; Wang SN; Lee KT; Lin CS; Kuo KK
Cancer Biomark; 2020; 28(3):341-350. PubMed ID: 32390596
[TBL] [Abstract][Full Text] [Related]
11. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.
Liao J; Zeng DN; Li JZ; Hua QM; Xiao Z; He C; Mao K; Zhu LY; Chu Y; Wen WP; Zheng L; Wu Y
Hepatol Int; 2020 Jan; 14(1):80-95. PubMed ID: 31802389
[TBL] [Abstract][Full Text] [Related]
12. CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma.
Chen Y; Li L; Lan J; Cui Y; Rao X; Zhao J; Xing T; Ju G; Song G; Lou J; Liang J
Mol Cancer; 2022 Jan; 21(1):11. PubMed ID: 34983546
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
14. Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma.
Yoo JJ; Yu SJ; Na J; Kim K; Cho YY; Lee YB; Cho EJ; Lee JH; Kim YJ; Youn H; Yoon JH
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875800
[TBL] [Abstract][Full Text] [Related]
15. TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma.
Tan W; Luo X; Li W; Zhong J; Cao J; Zhu S; Chen X; Zhou R; Shang C; Chen Y
EBioMedicine; 2019 Feb; 40():446-456. PubMed ID: 30594557
[TBL] [Abstract][Full Text] [Related]
16. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.
Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY
Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970
[TBL] [Abstract][Full Text] [Related]
17. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
[TBL] [Abstract][Full Text] [Related]
18. Strategies for HCC target discovery.
Molina-Sánchez P; Lujambio A
Aging (Albany NY); 2017 Apr; 9(4):1088-1089. PubMed ID: 28455974
[No Abstract] [Full Text] [Related]
19. Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids.
Wang S; Wang Y; Xun X; Zhang C; Xiang X; Cheng Q; Hu S; Li Z; Zhu J
J Exp Clin Cancer Res; 2020 Jan; 39(1):22. PubMed ID: 31992334
[TBL] [Abstract][Full Text] [Related]
20. Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na
Jiang W; Li G; Li W; Wang P; Xiu P; Jiang X; Liu B; Sun X; Jiang H
Sci Rep; 2018 Jun; 8(1):9706. PubMed ID: 29946188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]